Hippocampal harms, protection and recovery following regular cannabis use

Translational Psychiatry

Volumn 6, Issue 1, 2016, Pages

  Yucel M ^a   Lorenzetti, V ^a   Suo, C ^a   Zalesky, A ^b   Fornito, A ^a   Takagi, M J ^b   Lubman, D I ^a   Solowij, N ^c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL;

ADULT; CANNABIS ADDICTION; DRUG EFFECTS; FEMALE; HIPPOCAMPUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY;

ADULT; CANNABIDIOL; CANNABIS; DRONABINOL; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA ABUSE;

EID: 84964045762     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2015.201     Document Type: Article

References (42)

1. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219–2227.
2. Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008; 65: 694–701.
3. Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012; 135: 2245–2255.
4. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF et al. The acute effects of synthetic intravenous delta 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009; 31: 1607–1616.
5. D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594–608.
6. Morgan CJA, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 2012; 4: 391–400.
7. Bhattacharyya S. Neurobiological and neurocognitive basis of the effects of cannabinoids in animals and man: therapeutic potential of cannabinoids in psy-chiatry. Curr Pharm Des 2014; 20: 2069–2071.
8. Hermann D, Schneider M. Potential protective effects of cannabidiol on neuroa-natomical alterations in cannabis users and psychosis: a critical review. Curr Pharm Des 2012; 18: 4897–4905.
9. Schiavon AP, Soares LM, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM. Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox Res 2014; 26: 307–316.
10. Sobell LC, Sobell MB. Timeline Follow-Back: A Technique For Assessing Self-reported Alcohol Consumption. Humana Press: Totowa, NJ, USA, 1992.
11. Takagi M, Lubman DI, Cotton S, Fornito A, Baliz Y, Tucker A et al. Executive control among adolescent inhalant and cannabis users. Drug Alcohol Rev 2011; 30: 629–637.
12. Takagi M, Yücel M, Cotton SM, Baliz Y, Tucker A, Elkins K et al. Verbal memory, learning, and executive functioning among adolescent inhalant and cannabis users. J Stud Alcohol Drugs 2011; 72: 96–105.
13. Takagi MJ, Yücel M, Lubman DI. The dark side of sniffing: paint colour affects intoxication experiences among adolescent inhalant users. Drug Alcohol Rev 2010; 29: 452–455.
14. Yücel M, Zalesky A, Takagi MJ, Bora E, Fornito A, Ditchfield M et al. White-matter abnormalities in adolescents with long-term inhalant and cannabis use: a diffusion magnetic resonance imaging study. J Psychiatry Neurosci 2010; 35: 409–412.
15. Daeppen JB, Yersin B, Landry U, Pécoud A, Decrey H. Reliability and validity of the Alcohol Use Disorders Identification Test (AUDIT) imbedded within a general health risk screening questionnaire: results of a survey in 332 primary care patients. Alcohol Clin Exp Res 2000; 24: 659–665.
16. First MB, Spitzer RL, Gibbon M, JBM Williams. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Non-Patient Edition. New York State Psychiatric Institute: New York, NY, USA, 1996.
17. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA 2010; 108: 3017–3022.
18. Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage 2008; 40: 570–582.
19. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001; 14: 260–264.
20. Hammen T, Stadlbauer A, Tomandl B, Ganslandt O, Pauli E, Huk W et al. Short TE single-voxel 1H-MR spectroscopy of hippocampal structures in healthy adults at 1.5 Tesla: how reproducible are the results? NMR Biomed 2005; 18: 195–201.
21. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 2011; 114: 242–245.
22. Matochik JA, Eldreth DA, Cadet JL, Bolla K. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 2005; 77: 23–30.
23. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D et al. Can-nabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One 2011; 6: e28668.
24. Lorenzetti V, Solowij N, Fornito A, Lubman DI, Yücel M. The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. Curr Pharm Des 2014; 20: 2138–2167.
25. Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neuro-cognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev 2013; 23: 117–137.
26. Bhattacharyya S, Crippa J, Martin-Santos R, Winton-Brown T, Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des 2009; 15: 2603–2614.
27. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2009; 35: 764–774.
28. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, McGuire PK. Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Curr Pharm Des 2012; 18: 5045–5054.
29. Martin-Santos RA, Crippa J, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and can-nabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012; 18: 4966–4979.
30. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S et al. Modulation of effective connectivity during emotional processing by delta-9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010; 13: 421–432.
31. Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R et al. Disruption of frontal theta coherence by delta9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 2011; 36: 827–836.
32. Bhattacharyya S, Falkenberg I, Martin-Santos R, Atakan Z, Crippa JA, Giampietro V et al. Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology 2014; 40: 1343–1352.
33. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O’Carroll C et al. Modulation of mediotemporal and ventrostriatal function in humans by δ9-tetrahydrocannabinol: a neural basis for the effects of cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66: 442–451.
34. Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sci 1995; 56: 2119–2126.
35. Sneider JT, Pope HG Jr, Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA. Differences in regional blood volume during a 28-day period of abstinence in chronic cannabis smokers. Eur Neuropsychopharmacol 2008; 18: 612–619.
36. Thames AD, Arbid N, Sayegh P. Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav 2014; 39: 994–999.
37. Winward JL, Hanson KL, Tapert SF, Brown SA. Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements. J Int Neuropsychol Soc 2014; 20: 784–795.
38. Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H et al. Neuropsycholo-gical consequences of regular marijuana use: a twin study. Psychol Med 2004; 34: 1239–1250.
39. Hooper SR, Woolley D, De Bellis MD. Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. Psycho-pharmacology (Berl) 2014; 231: 1467–1477.
40. Bosker WM, Karschner EL, Lee D, Goodwin RS, Hirvonen J, Innis RB et al. Psy-chomotor function in chronic daily cannabis smokers during sustained absti-nence. PLoS One 2013; 8: e53127.
41. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109: e2657–e2664.
42. Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 2013; 8: e70052.